Taiwan · Delayed Price · Currency is TWD PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 167.73 billion. The enterprise value is 147.04 billion.
| Market Cap | 167.73B |
| Enterprise Value | 147.04B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Aug 11, 2025 |
Share Statistics
PharmaEssentia has 369.85 million shares outstanding. The number of shares has increased by 0.44% in one year.
| Current Share Class | 369.85M |
| Shares Outstanding | 369.85M |
| Shares Change (YoY) | +0.44% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 8.94% |
| Owned by Institutions (%) | 8.52% |
| Float | 291.08M |
Valuation Ratios
The trailing PE ratio is 35.02 and the forward PE ratio is 24.28.
| PE Ratio | 35.02 |
| Forward PE | 24.28 |
| PS Ratio | 12.14 |
| PB Ratio | 5.64 |
| P/TBV Ratio | 5.68 |
| P/FCF Ratio | 55.44 |
| P/OCF Ratio | 38.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.59, with an EV/FCF ratio of 48.60.
| EV / Earnings | 30.60 |
| EV / Sales | 10.64 |
| EV / EBITDA | 34.59 |
| EV / EBIT | 37.64 |
| EV / FCF | 48.60 |
Financial Position
The company has a current ratio of 6.83, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.83 |
| Quick Ratio | 6.45 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.30 |
| Interest Coverage | 155.89 |
Financial Efficiency
Return on equity (ROE) is 17.21% and return on invested capital (ROIC) is 8.46%.
| Return on Equity (ROE) | 17.21% |
| Return on Assets (ROA) | 7.68% |
| Return on Invested Capital (ROIC) | 8.46% |
| Return on Capital Employed (ROCE) | 12.80% |
| Revenue Per Employee | 105.46M |
| Profits Per Employee | 36.68M |
| Employee Count | 131 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -982.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.94% in the last 52 weeks. The beta is -0.05, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -6.94% |
| 50-Day Moving Average | 504.36 |
| 200-Day Moving Average | 494.85 |
| Relative Strength Index (RSI) | 42.23 |
| Average Volume (20 Days) | 1,922,336 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 13.82 billion and earned 4.80 billion in profits. Earnings per share was 12.95.
| Revenue | 13.82B |
| Gross Profit | 12.32B |
| Operating Income | 3.91B |
| Pretax Income | 3.82B |
| Net Income | 4.80B |
| EBITDA | 4.03B |
| EBIT | 3.91B |
| Earnings Per Share (EPS) | 12.95 |
Balance Sheet
The company has 21.58 billion in cash and 892.99 million in debt, giving a net cash position of 20.69 billion or 55.94 per share.
| Cash & Cash Equivalents | 21.58B |
| Total Debt | 892.99M |
| Net Cash | 20.69B |
| Net Cash Per Share | 55.94 |
| Equity (Book Value) | 29.75B |
| Book Value Per Share | 80.44 |
| Working Capital | 22.91B |
Cash Flow
In the last 12 months, operating cash flow was 4.32 billion and capital expenditures -1.29 billion, giving a free cash flow of 3.03 billion.
| Operating Cash Flow | 4.32B |
| Capital Expenditures | -1.29B |
| Free Cash Flow | 3.03B |
| FCF Per Share | 8.18 |
Margins
Gross margin is 89.17%, with operating and profit margins of 28.29% and 34.78%.
| Gross Margin | 89.17% |
| Operating Margin | 28.29% |
| Pretax Margin | 27.67% |
| Profit Margin | 34.78% |
| EBITDA Margin | 29.18% |
| EBIT Margin | 28.29% |
| FCF Margin | 21.90% |
Dividends & Yields
This stock pays an annual dividend of 0.99, which amounts to a dividend yield of 0.22%.
| Dividend Per Share | 0.99 |
| Dividend Yield | 0.22% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.62% |
| Buyback Yield | -0.44% |
| Shareholder Yield | -0.23% |
| Earnings Yield | 2.86% |
| FCF Yield | 1.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 11, 2025. It was a forward split with a ratio of 1.10973093.
| Last Split Date | Sep 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.10973093 |
Scores
PharmaEssentia has an Altman Z-Score of 26.07 and a Piotroski F-Score of 6.
| Altman Z-Score | 26.07 |
| Piotroski F-Score | 6 |